MiNK Therapeutics (INKT) Competitors $9.09 +0.06 (+0.61%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. ALEC, SAVA, LXEO, TELO, PRQR, GNLX, NLTX, JMAC, ENTA, and EPRXShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Alector (ALEC), Cassava Sciences (SAVA), Lexeo Therapeutics (LXEO), Telomir Pharmaceuticals (TELO), ProQR Therapeutics (PRQR), Genelux (GNLX), Neoleukin Therapeutics (NLTX), Maxpro Capital Acquisition (JMAC), Enanta Pharmaceuticals (ENTA), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Alector Cassava Sciences Lexeo Therapeutics Telomir Pharmaceuticals ProQR Therapeutics Genelux Neoleukin Therapeutics Maxpro Capital Acquisition Enanta Pharmaceuticals Eupraxia Pharmaceuticals MiNK Therapeutics (NASDAQ:INKT) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Does the MarketBeat Community believe in INKT or ALEC? Alector received 139 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 77.27% of users gave MiNK Therapeutics an outperform vote while only 60.94% of users gave Alector an outperform vote. CompanyUnderperformOutperformMiNK TherapeuticsOutperform Votes1777.27% Underperform Votes522.73% AlectorOutperform Votes15660.94% Underperform Votes10039.06% Do analysts rate INKT or ALEC? MiNK Therapeutics currently has a consensus price target of $37.50, indicating a potential upside of 312.77%. Alector has a consensus price target of $3.50, indicating a potential upside of 178.88%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe MiNK Therapeutics is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14 Is INKT or ALEC more profitable? MiNK Therapeutics has a net margin of 0.00% compared to Alector's net margin of -257.54%. MiNK Therapeutics' return on equity of 0.00% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -189.14% Alector -257.54%-108.77%-27.03% Which has more volatility & risk, INKT or ALEC? MiNK Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Does the media refer more to INKT or ALEC? In the previous week, Alector had 3 more articles in the media than MiNK Therapeutics. MarketBeat recorded 4 mentions for Alector and 1 mentions for MiNK Therapeutics. Alector's average media sentiment score of 0.57 beat MiNK Therapeutics' score of 0.40 indicating that Alector is being referred to more favorably in the news media. Company Overall Sentiment MiNK Therapeutics Neutral Alector Positive Do insiders and institutionals have more ownership in INKT or ALEC? 2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 20.6% of MiNK Therapeutics shares are held by company insiders. Comparatively, 9.1% of Alector shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, INKT or ALEC? MiNK Therapeutics has higher earnings, but lower revenue than Alector. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$22.46M-$2.92-3.11Alector$100.56M1.24-$130.39M-$1.23-1.02 SummaryAlector beats MiNK Therapeutics on 10 of the 17 factors compared between the two stocks. Remove Ads Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.03M$2.98B$5.62B$7.73BDividend YieldN/A1.55%5.33%4.02%P/E Ratio-2.3330.5423.5418.59Price / SalesN/A412.02371.7888.87Price / CashN/A168.6838.1734.64Price / Book-1.743.746.824.11Net Income-$22.46M-$71.95M$3.20B$247.18M7 Day Performance6.01%-10.49%-5.42%-3.93%1 Month Performance1.51%-15.51%-0.14%-6.33%1 Year Performance0.02%-30.28%7.96%-1.93% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.2267 of 5 stars$9.09+0.6%$37.50+312.8%-0.6%$36.03MN/A-2.3330Gap DownALECAlector3.8157 of 5 stars$1.37+1.5%$3.50+155.5%-78.6%$135.75M$100.56M-0.81270Gap DownSAVACassava Sciences3.8647 of 5 stars$2.80-1.4%$111.50+3,882.1%-91.9%$135.26MN/A-2.0330Short Interest ↓Gap DownLXEOLexeo Therapeutics3.1582 of 5 stars$4.09+50.9%$23.60+477.0%-73.9%$135.24M$650,000.00-1.2958Earnings ReportAnalyst RevisionGap DownHigh Trading VolumeTELOTelomir Pharmaceuticals2.353 of 5 stars$4.53-0.7%$15.00+231.1%-23.3%$134.83MN/A-7.811Gap DownPRQRProQR Therapeutics1.904 of 5 stars$1.65flat$9.50+475.8%-38.9%$134.77M$18.91M-5.16180Positive NewsGNLXGenelux1.2551 of 5 stars$3.89-1.0%$18.25+369.2%-52.1%$134.35M$8,000.00-4.0910Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionGap DownNLTXNeoleukin TherapeuticsN/A$14.21-6.7%N/A-71.5%$133.55MN/A-4.5790High Trading VolumeJMACMaxpro Capital AcquisitionN/A$9.90-4.7%N/A+914.7%$132.94MN/A0.002,021Gap DownENTAEnanta Pharmaceuticals3.9618 of 5 stars$6.20-1.7%$17.25+178.2%-67.3%$132.27M$66.59M-1.25160EPRXEupraxia Pharmaceuticals2.8133 of 5 stars$3.65-4.6%$10.50+188.1%N/A$129.93MN/A-5.0629Upcoming EarningsGap Down Remove Ads Related Companies and Tools Related Companies Alector Competitors Cassava Sciences Competitors Lexeo Therapeutics Competitors Telomir Pharmaceuticals Competitors ProQR Therapeutics Competitors Genelux Competitors Neoleukin Therapeutics Competitors Maxpro Capital Acquisition Competitors Enanta Pharmaceuticals Competitors Eupraxia Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredAI Boom Takes a Shocking Turn…AI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a br...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
